Firmonertinib shows durable antitumor activity in EGFR-mutated lung cancer trial

A Phase Ib trial led by The University of Texas MD Anderson Cancer Center demonstrated that firmonertinib, a targeted therapy, achieved durable antitumor activity in patients with EGFR PACC-mutated non-small cell lung cancer. This supports a treatment selection approach based on the structural features of uncommon EGFR mutations.

Originally published by gnews